EUROAPI SASU (EAPI.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:EAPI - FR0014008VX5 - Common Stock
EAPI.PA Key Statistics, Chart & Performance
The current stock price of EAPI.PA is 2.136 EUR. In the past month the price decreased by -30.24%. In the past year, price decreased by -31.1%.
EAPI.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.91 | 201.34B | ||
| SNW.DE | SANOFI | 10.88 | 200.78B | ||
| 1SAN.MI | SANOFI | 10.69 | 197.40B | ||
| MRK.DE | MERCK KGAA | 14.97 | 55.52B | ||
| UCB.BR | UCB SA | 39.33 | 49.11B | ||
| UNC.DE | UCB SA | 39.36 | 49.15B | ||
| BAYN.DE | BAYER AG-REG | 7.4 | 38.84B | ||
| 1BAYN.MI | BAYER AG-REG | 7.12 | 37.38B | ||
| IPN.PA | IPSEN | 12.34 | 10.62B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.03 | 10.31B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 107.45 | 9.95B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.08 | 8.94B |
Related stock screener links
About EAPI.PA
Company Profile
EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
Company Info
EUROAPI SASU
15, rue Traversiere
Paris ILE-DE-FRANCE FR
Employees: 3187
Phone: 33189206200
EUROAPI SASU / EAPI.PA FAQ
Can you describe the business of EUROAPI SASU?
EUROAPI SA engages in manufacturing and supply of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France and currently employs 3,428 full-time employees. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
What is the stock price of EUROAPI SASU today?
The current stock price of EAPI.PA is 2.136 EUR. The price increased by 1.04% in the last trading session.
Does EUROAPI SASU pay dividends?
EAPI.PA does not pay a dividend.
How is the ChartMill rating for EUROAPI SASU?
EAPI.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists EAPI stock?
EAPI.PA stock is listed on the Euronext Paris exchange.
What is the GICS sector and industry of EAPI stock?
EUROAPI SASU (EAPI.PA) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of EAPI stock?
EUROAPI SASU (EAPI.PA) has a market capitalization of 204.18M EUR. This makes EAPI.PA a Micro Cap stock.
EAPI.PA Technical Analysis
EAPI.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EAPI.PA. EAPI.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
EAPI.PA Financial Highlights
Over the last trailing twelve months EAPI.PA reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 56.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.67% | ||
| ROE | -13.12% | ||
| Debt/Equity | 0.07 |
EAPI.PA Forecast & Estimates
13 analysts have analysed EAPI.PA and the average price target is 2.73 EUR. This implies a price increase of 27.98% is expected in the next year compared to the current price of 2.136.
For the next year, analysts expect an EPS growth of 65.03% and a revenue growth -3.72% for EAPI.PA